Increased Fungal Infections while using Emerging Therapies (Biologics and Small-molecule Inhibitors) for Treating Skin Diseases: A Review

키워드

참고문헌 (48)

1. Davis MR, "Fungal infections potentiated by biologics", Infect Dis Clin North Am, 34, pp.389~411 (2020)
2. Jourabchi N, "The risk of deep fungal infections during biologic therapy for psoriasis", J Eur Acad Dermatol Venereol, 28, pp.1277~1285 (2014)
3. Friedman DZP, "Emerging fungal infections:new patients, new patterns, and new pathogens", J Fungi(Basel), 5, pp.67~ (2019)
4. Tsiodras S, "Fungal infections complicating tumor necrosis factor alpha blockade therapy", Mayo Clin Proc, 83, pp.181~194 (2008)
5. Pérez-Sola MJ, "Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry", Med Clin(Barc), 137, pp.533~540 (2011)
6. Bongartz T, "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials", JAMA, 295, pp.2275~2285 (2006)
7. Favalli EG, "Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients", Autoimmun Rev, 8, pp.266~273 (2009)
8. Peyrin-Biroulet L, "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials", Clin Gastroenterol Hepatol, 6, pp.644~653 (2008)
9. Papp KA, "A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis", Br J Dermatol, 175, pp.273~286 (2016)
10. Hay RJ, "Candida infections and interleukin-17 inhibitors used in dermatology", Br J Dermatol, 177, pp.10~11 (2017)
11. Puel A, "Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity", Science, 332, pp.65~68 (2011)
12. Burstein VL, "IL-17-mediated immunity controls skin infection and T helper 1 response during experimental Microsporum canis dermatophytosis", J Invest Dermatol, 138, pp.1744~1753 (2018)
13. Puerta-Arias JD, "The role of the interleukin-17 axis and neutrophils in the pathogenesis of endemic and systemic mycoses", Front Cell Infect Microbiol, 10, pp.595301~ (2020)
14. Sawada Y, "Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia", lymphoma, 2012, pp.18, 3772~3779
15. van de Kerkhof PC, "Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis", J Am Acad Dermatol, 75, pp.83~98 (2016)
16. Mease P, "Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials", Arthritis Care Res(Hoboken), 71, pp.367~378 (2019)
17. Kagami S, "IL-23and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans", J Immunol, 185, pp.5453~5462 (2010)
18. Lebwohl M, "Phase 3 studies comparing brodalumab with ustekinumab in psoriasis", N Engl J Med, 373, pp.1318~1328 (2015)
19. Papp KA, "Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis : final results from 5 years of follow-up", Br J Dermatol, 168, pp.844~854 (2013)
20. Gordon KB, "Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials", J Am Acad Dermatol, 66, pp.742~751 (2012)
21. Tavakolpour S, "Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review", Int Immunopharmacol, 54, pp.131~138 (2018)
22. : CD19, CD20and CD52), "Clin Microbiol Infect", 2018, S71~S82
23. Bechman K, "Small-molecule protein kinases inhibitors and the risk of fungal infections", Current Fungal Infection Reports, 13, pp.229~243 (2019)
24. Zimmerman O, "Risks of ruxolitinib in STAT1 gain-of-functionassociated severe fungal disease", Open Forum Infect Dis, 4, pp.ofx202~ (2017)
25. Stephen-Victor E, "Aspergillus fumigatus cell wall α-(1,3)-glucan stimulates regulatory T-cell polarization by inducing PD-L1 expression on human dendritic cell", J Infect Dis, 216, pp.1281~1294 (2017)
26. Daver N, "Checkpoint inhibitors and aspergillosis in AML : the double hit hypothesis", Lancet Oncol, 18, pp.1571~1573 (2017)
27. Wurster S, "Protective activity of programmed cell death protein 1 blockade and synergy with caspo"fungin in a murine invasive pulmonary aspergillosis model", J Infect Dis, 222, pp.989~994 (2020)
28. Del Castillo M, "The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma", Clin Infec Dis, 63, pp.1490~1493 (2016)
29. Maertens JA, "European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia", J Antimicrob Chemother, 73, pp.3221~3230 (2018)
30. Filler SG, "Tumor necrosis factor inhibition and invasive fungal infections", Clin Infect Dis, 41(Suppl 3), pp.S208~212 (2005)
31. Wallis RS, "Granulomatous infectious diseases associated with tumor necrosis factor antagonists", Clin Infect Dis, 38, pp.1261~1265 (2004)
32. Hoang JK, "Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy", Pediatr Dermatol, 24, pp.285~288 (2007)
33. Seminario-Vidal L, "Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis", J Drugs Dermatol, 14, pp.901~902 (2015)
34. Tuxen AJ, "Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin", Br J Dermatol, 157, pp.1067~1068 (2007)
35. Osório F, "Primary cutaneous asper"gillosis complicating tumor necrosis factor-α blockade therapy in a patient with psoriasis", Actas Dermosifiliogr, 103, pp.939~941 (2012)
36. Kamili QU, "Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy", J Drugs Dermatol, 9, pp.57~60 (2010)
37. Lee JH, ". Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept", Arthritis Rheum, 46, pp.2565~2570 (2002)
38. Harigai M, "Pneumocystis pneumonia associated with infliximab in Japan", N Engl J Med, 357, pp.1874~1876 (2007)
39. Podlipnik S, "Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab : Case report and review of the literature", Australas J Dermatol, 58, pp.e44~e47 (2017)
40. Lahiff C, "Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis", Ir J Med Sci, 176, pp.309~311 (2007)
41. Lussana F, "Ruxolitinib-associated infections : A systematic review and meta-analysis", Am J Hematol, 93, pp.339~347 (2018)
42. Arriola E, "Immunosuppression for ipilimumabrelated toxicity can cause Pneumocystis pneumonia but spare antitumor immune control", Oncoimmunology, 4, pp.e1040218~ (2015)
43. Saunte DM, "Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management", Br J Dermatol, 177, pp.47~62 (2017)
44. Quach OL, "Perianal dermatophytosis during secukinumab therapy for plaque psoriasis", JAMA Dermatol, 152, pp.486~487 (2016)
45. Neema S, "Widespread superficial dermatophytosis in patient on secukinumab for treatment of chronic plaque psoriasis", Indian Dermatol Online J, 10, pp.76~78 (2019)
46. Lowther AL, "Invasive Trichophyton rubrum infection occurring with infliximab and long-term prednisone treatment", J Cutan Med Surg, 11, pp.84~88 (2007)
47. de Beer FSA, "Dupilumab facial redness : Positive effect of itraconazole", JAAD Case Rep, 5, pp.888~891 (2019)
48. Balestri R, "Pityriasis versicolor during anti-TNF-αmonoclonal antibody therapy : therapeutic considerations", Mycoses, 55, pp.444~446 (2012)

관련 논문AI추천